Applied Clinical Trials

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of policy shifts on vaccine trial design and patient perceptions. Stricter regulations could increase trial complexity, affecting recruitment and retention. Kong emphasized behavioral insights as crucial to understanding patient motivation and mitigating dropouts.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Krinx Kong, chief commercial officer, Cognivia, discussed the potential impacts of policy shifts on vaccine trial design and patient perceptions. Stricter regulations could increase trial complexity, affecting recruitment and retention. Kong emphasized behavioral insights as crucial to understanding patient motivation and mitigating dropouts.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

Boehringer Ingelheim has announced the start of the JADE Phase II clinical trial (NCT06769048), evluating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA). BI 1584862, a phospholipid modulator, was discovered and developed in-house by Boehringer.

1 week ago | appliedclinicaltrialsonline.com | Davy James

Updated data from the pivotal Phase III ELATIVE trial (NCT04526665) show Iqirvo (elafibranor) significantly improved fatigue in patients with primary biliary cholangitis (PBC) after 52 weeks.1,2 The updated trial results, presented at the European Association for the Study of the Liver congress, demonstrated that these treatment effects were independent of pruritus and bolstered by mechanistic proteomic analyses from the trial, according to the investigators.

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

Gilead has announced final data from its Phase III MYR301 clinical trial of bulevirtide in patients with chronic hepatitis delta virus (HDV). At either a 2 mg or 10 mg dose, the first-in-class entry inhibitor maintained virologic suppression for almost two years following treatment after achieving undetectable HDV RNA at end of treatment in 36% of adults living with HDV who were treated.